Latest Articles and Analysis

Patients face multiple monkeypox barriers: disorganized state websites, limited vaccine access, reporting gaps.

ADAP Fireside Chat addresses counterfeit medications, 340B reform, and public health workforce sustainability.

S.4395 would divert Ryan White resources from PLWHA to PrEP, threatening the safety net for vulnerable populations.

Provider language shows negative bias toward Black patients at 2.5x rate, undermining care engagement.

Overdose Awareness Day calls for holistic interventions addressing SUD as a health issue, not criminal one.

White House releases federal implementation plan with 380+ action items for National HIV/AIDS Strategy.

European Commission approves lenacapavir, a novel six-month injectable for treatment-resistant HIV.

Stigma drives opposition to harm reduction programs like safe consumption sites despite strong evidence.

Only 35% of privately insured and 23% of Medicaid patients initiate HCV treatment due to payer barriers.

US monkeypox response: 31% of cases among Black persons, vaccine distribution equity concerns persist.

Innovative HIV medications available but inaccessible: payer barriers block Cabenuva and Apretude access.

Q3 2022 review of HCV drug access across ADAPs, Medicaid, and comprehensive harm reduction programs.

Sustainable advocacy requires long-term investment beyond quarterly financial commitments.

Community-based low-barrier HCV treatment for PWID significantly improves liver health outcomes.

85,000+ fake HIV medication bottles distributed through counterfeiting rings endanger patient safety.

West Virginia's fragmented HIV services across four entities creates barriers; centralization needed.

Federal executive actions protect LGBTQ people as states restrict gender-affirming care and trans rights.

ADAP Advocacy Association Fireside Chats resume with discussions on utilization management and EHE progress.

Conference examines HIV and methamphetamine use intersection among MSM and transgender communities.

2020 CDC HIV surveillance reveals COVID-19's impact on HIV prevention and testing with decreased diagnoses and increased deaths.